Healthcare / Medical DevicesWarsaw
$76.80
-0.50 (-0.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.6M · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$713M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.6%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-6.7M · FCF $-11.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $188000.00 | $225000.00 | $246000.00 |
| Net Income | $-6.7M | $-6.7M | $37.6M | $-5.1M | $-4.9M |
| EBITDA | $-6.5M | $-6.5M | $37.9M | $-4.7M | $-4.6M |
| EPS | -0.86 | -0.86 | 5.62 | -0.79 | -0.79 |
| Gross Margin | — | — | -13.8% | 33.3% | 54.9% |
| Operating Margin | — | — | -2491.5% | -2568.4% | -2032.1% |
| Net Margin | — | — | 19987.8% | -2254.2% | -2002.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Current Ratio | 6.87 | 6.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.7M | $-11.7M | $-10.6M | $-9.9M | $-6.3M |
| Returns | |||||
| ROE | -7.6% | -7.6% | 46.4% | -15.3% | -13.3% |
| Valuation | |||||
| P/E | — | — | 1.43 | — | — |
| EV/EBITDA | — | — | 1.19 | — | — |
| P/B | 6.80 | 6.80 | 0.66 | 2.02 | 2.44 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -16.4% | -8.5% | — |
| EPS Growth | -115.3% | -115.3% | 811.4% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+885.0%
Start / end P/E
n/dx → n/dx
EPS bridge
5.62 → -0.86
Residual
+885.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.